Pediatrix Medical Group, Inc.

Pediatrix Medical Group, Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Pediatrix Medical Group, Inc. has 81.22M shares outstanding.

As of June 30, 2026, Pediatrix Medical Group, Inc. maintains a current ratio of 1.32, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 70.37, indicating elevated leverage, while an interest coverage ratio of 6.99 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Pediatrix Medical Group, Inc. posted a return on equity (ROE) of 20.39, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 10.92 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 8.26, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 13.48, useful for judging operating efficiency across full business cycles. The company generates approximately 5.21M in revenue per employee across its workforce of 6,545.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Pediatrix Medical Group, Inc. recorded 898.23M in income tax expense. That works out to an effective tax rate of 22.73, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 3.95B, leaving 3.05B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 15, 2026, Pediatrix Medical Group, Inc.'s stock has gained approximately 67.61% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Pediatrix Medical Group, Inc. generated 34.08B in revenue and converted that into 3.05B in net income, yielding earnings per share of 36.52. EBITDA reached 4.17B, while operating income came in at 4.20B.

As of June 30, 2026, Pediatrix Medical Group, Inc. holds 7.06B in cash and equivalents against 10.83B in total debt, resulting in a net debt position of 5.16B. Total book value stands at 15.39B, with working capital of 2.77B providing operational flexibility.

Pediatrix Medical Group, Inc. produced 4.31B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -318.87M in capital expenditures, free cash flow totaled 3.99B - equivalent to 48.55 per share.

Over the twelve months ended June 30, 2026, Pediatrix Medical Group, Inc. posted a gross margin of 26.24, reflecting its pricing power and cost economics. The operating margin of 12.34 and net profit margin of 8.96 provide insight into operational efficiency.

Pediatrix Medical Group, Inc.'s most recent stock split took place on December 20, 2013 with a 1:2 split ratio.